Mohammed Maniruzzaman, PhD
Assistant Professor in Pharmaceutics and Drug Delivery
Division of Molecular Pharmaceutics and Drug Delivery
University of Texas at Austin
Dr Mo Maniruzzaman is an Assistant Professor in Pharmaceutics and Drug Delivery at the College of Pharmacy, The University of Texas (UT) at Austin. He leads the newly established ‘Pharmaceutical Engineering and 3D Printing (PharmE3D)’ Lab. He obtained his PhD from the University of Greenwich, UK with no corrections (RDC/12/M-3/14, UoG) and two accompanying awards including the Vice Chancellor’s Award in 2013 for the outstanding performance in his doctoral research. Prior to his current appointment at UT Austin, Dr Maniruzzaman was a Lecturer (2017-2019) in Pharmaceutics and Drug Delivery at the University of Sussex, UK. His lab has received 19 prestigious awards and scholarships (6 awards in 2021) for the outstanding academic/scholarly work including Gold Medals, ORSAS Scholarship 2009, VC Award 2013, STARs Award 2019, MDPI Pharmaceutics SI Best Paper Award 2020, Reseath4Impact 2020, IPEC Foundation Graduate Student Award, Texas Global FRSG 2021, and Research Reboot 2021.
Dr Maniruzzaman has extensive research experience in pharmaceutical engineering, advanced drug delivery, additive manufacturing (e.g., 3D printing/bioprinting), and medical devices. This is reflected by authorship of more than 70 published papers (in ACS, Elsevier, RSC, and AAPS Q1 journals), 10 issued patents and patent applications, 3 books, 10 book chapters, and more than 40 conference presentations. The PharmE3D Lab led by Dr Maniruzzaman has invented various proprietary technologies which have been licensed to multiple pharmaceutical companies such as CoM3D Limited. He serves on the Editorial Board of multiple international peer-reviewed journals including AAPS PharmSciTech, Current Drug Delivery, Legume Science, and Heliyon. Dr Maniruzzaman has secured >$2 million research funding from federal and non-federal organizations since joining UT Austin in 2019 with three major federal grants pending including one NIH R01 (grant value ~$4 million).